425 filed Jun 8, 2026 at 08:35 ET
Standard BioTools (LAB) announced a transformative all-stock reverse merger with private biotech Treeline Biosciences. Treeline is valued at $2.5 billion, while LAB's net cash implies an equity value of ~$460 million. Former Treeline stockholders will own ~84% of the combined company on a fully diluted basis, with LAB holders retaining ~16%. LAB also plans to issue CVRs to its stockholders tied to monetization of its legacy businesses, capped at 76 million shares. The deal requires LAB stockholder approval and is expected to close in H2 2026.